Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.50 |
| ▸ | CNR2 | P34972 | 6/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898278 | 1.00 | CNR1 (0.50) | CNR1CNR2PTGER1SCN8ASCN10A | |
| SCHEMBL9896699 | 1.00 | CNR1 (0.50) | CNR1CNR2PTGER1SCN8ASCN10A | |
| SCHEMBL9896537 | 1.00 | CNR1 (0.50) | CNR1CNR2PTGER1SCN8ASCN10A | |
| SCHEMBL9896146 | 0.98 | CNR1 (0.48) | CNR1CNR2PTGER1SCN8ASCN10A | |
| SCHEMBL9897308 | 0.98 | CNR1 (0.48) | CNR1CNR2PTGER1SCN8ASCN10A | |
| SCHEMBL9896086 | 0.98 | CNR1 (0.48) | CNR1CNR2PTGER1SCN8ASCN10A | |
| SCHEMBL9897995 | 0.98 | CNR1 (0.48) | CNR1CNR2PTGER1SCN8ASCN10A | |
| SCHEMBL9897913 | 0.90 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL9899586 | 0.90 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL9898818 | 0.90 | CNR1 (0.47) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | CNR1 3069/4885CNR2 2377/4885PTGER1 280/4885 |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE12, PDE5A, PDE4A | CNR1 3001/4885CNR2 2118/4885PTGER1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.